Extended release nicotinic acid is a promising agent for phosphate control in hemodialysis [2]

Kidney International

Volumn 69, Issue 7, 2006, Pages 1281-

  Sampathkumar, K ^a   Sooraj, Y S ^a   Ajeshkumar, R P ^a  

^a Meenakshi Mission Hospital   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM PHOSPHATE; LANTHANUM CARBONATE; NICOTINIC ACID; PHOSPHATE; SEVELAMER;

CLINICAL ARTICLE; COST BENEFIT ANALYSIS; DELAYED DRUG RELEASE; DISEASE CONTROL; DRUG EFFICACY; HEMODIALYSIS; HUMAN; HYPERPHOSPHATEMIA; LETTER; PRIORITY JOURNAL;

HUMANS; NIACIN; PHOSPHATES; RENAL DIALYSIS; THROMBOCYTOPENIA;

EID: 33645517884     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5000258     Document Type: Letter

References (4)

1. Rottembourg JB, Launay-Vacher V et al. Thrombocytopenia induced by nicotinamide in hemodialysis patients. Kidney international 2005; 68: 2911-2912.
2. Eto N, Miyata Y et al. Nicotinamide prevents the development of hyperphophatemia by suppressing intestinal sodium dependent phosphate transporter in rats with adenine induced renal failure. Nephrol Dial Transplant 2005; 20: 1378-1384.
3. Takahashi Y, Tanaka A et al. Nicotinamide suppresses hyperphosphatemia in hemodialysis patients. Kidney Int 2004; 65: 1099-1104.
4. Sampathkumar K, Selvam M, Sooraj YS et al. Extended release nicotinic acid - a novel oral agent for phosphate control. Int Urol Nephrol 2006; 38: 171-174.